June 20, 2024 11:39 AM EDTUpdated June 21, 04:38 AM
Pharma
Manufacturing

Cor­rect­ed: Emer­gent sells Bal­ti­more fa­cil­i­ty for $30M

Max Bayer

Pharma Reporter

Emer­gent BioSo­lu­tions is sell­ing off a Bal­ti­more man­u­fac­tur­ing site for $30 mil­lion to Bo­ra Phar­ma­ceu­ti­cals.

“The de­ci­sion to sell our Cam­den man­u­fac­tur­ing fa­cil­i­ty is aligned …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times